Cara Therapeutics Granted U.S. Patent #11684674: Oral formulations of kappa opioid receptor agonists
Portfolio Pulse from Charles Gross
Cara Therapeutics has been granted U.S. Patent #11684674 for oral formulations of kappa opioid receptor agonists, which could potentially lead to new treatments for pain and pruritus.
June 27, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cara Therapeutics' granted patent for oral formulations of kappa opioid receptor agonists may lead to new treatments and boost the company's product pipeline.
The granted patent directly pertains to Cara Therapeutics' product development and could potentially lead to new treatments for pain and pruritus. This may expand the company's product pipeline, attract investor interest, and drive growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100